B7-33
Also known as: B7-33 peptide, single-chain relaxin mimetic, H2 relaxin B-chain analogue, relaxin peptidomimetic, single-B-chain relaxin derivative
Synthetic single-chain peptide; functionally selective RXFP1 (Relaxin Family Peptide Receptor 1) agonist; relaxin mimetic
What it is
Researchers are studying B7-33 for its potential to reduce fibrosis — the buildup of scar tissue — in the heart, lungs, and kidneys. It activates the same protective receptor as relaxin, a natural hormone the body uses during pregnancy to remodel tissue. No FDA-approved use; evidence comes from animal studies and early in vitro work.
The scientific side
B7-33 is a synthetic single-chain peptide derived from the B-chain of human relaxin-2 (H2 relaxin). It binds to and activates the G protein-coupled receptor RXFP1 (Relaxin Family Peptide Receptor 1), acting as a functionally selective agonist by preferentially activating the pERK1/2 (extracellular signal-regulated kinase 1/2) pathway over the cAMP signaling pathway in cells that endogenously express RXFP1. This functional selectivity distinguishes B7-33 from native H2 relaxin, which strongly activates both cAMP and ERK pathways; the strong cAMP activation of H2 relaxin has been associated with potential tumor-promoting actions. The anti-fibrotic actions of B7-33 involve activation of RXFP1-angiotensin II type 2 receptor heterodimers, leading to downstream signaling through pERK1/2 and the collagen-degrading enzyme matrix metalloproteinase-2 (MMP-2). In the cardiovascular context, B7-33 reduces infarct size and adverse cardiac remodeling partly by attenuating cardiomyocyte death and endoplasmic reticulum stress via an ERK1/2-dependent mechanism. B7-33 has demonstrated poor affinity and potency in HEK cells overexpressing RXFP1, but equivalent potency to H2 relaxin in fibroblasts natively expressing RXFP1, where it replicates anti-fibrotic effects of the native hormone. In an anti-fibrotic nanotechnology context, B7-33 has also been described as an inducer of fibroblast quiescence.
Class: Synthetic single-chain peptide; functionally selective RXFP1 (Relaxin Family Peptide Receptor 1) agonist; relaxin mimetic
Administration & storage
- Administration
- Intravenous tail vein injection (acute bolus; PMID: 28478069)Subcutaneous injection (daily; PMID: 36753958)Intracerebroventricular injection (PMID: 34159282)Oral gavage via SPION nanoparticle conjugate (PMID: 41382190)Drinking water administration via SPION nanoparticle conjugate (PMID: 41382190)Intraperitoneal injection (vobramitamab duocarmazine ADC in xenograft models — note: this is an anti-B7-H3 ADCnot the B7-33 peptide; PMID: 41941262)
- Storage
- No storage conditions for B7-33 are described in the reviewed abstracts. The lipidated B7-33 derivative study reported an in vitro serum half-life of ~6 min for unmodified B7-33, extended to ~60 min with fatty-acid conjugation, but did not describe storage requirements.
- Cautions
- All B7-33 studies in the reviewed abstracts are preclinical (animal or in vitro); no human pharmacokinetic, safety, or tolerability data are available from the reviewed literature.,B7-33 has a short in vitro serum half-life of approximately 6 minutes in its unmodified form; this may limit systemic exposure duration.,Native H2 relaxin (the parent hormone) has been associated with tumor-promoting actions attributed to strong cAMP activation; B7-33 preferentially activates pERK over cAMP, and one abstract states B7-33 did not promote prostate tumor growth in preclinical models — however, long-term oncological safety of B7-33 has not been established in humans.,Sterile technique is required for any injectable preparation; this is a universal requirement for peptide injectables and not specific to B7-33.,No clinical trials of B7-33 peptide itself are described in the reviewed literature; extrapolation of animal dosing to humans is not supported by the reviewed evidence.
Legal & regulatory status
Not stated in reviewed literature — requires manual verification. No FDA approval or status is stated for B7-33 itself. Note: The parent hormone H2 relaxin (serelaxin) was investigated for acute heart failure and…
Not stated in reviewed literature — requires manual verification.
Not stated in reviewed literature — requires manual verification.
What it's studied for
- Anti-fibrotic effects (organ fibrosis — heart, lung, kidney) Animal studies only
- B7-33 prevented or reversed organ fibrosis and dysfunction in three pre-clinical rodent models of heart or lung disease with similar potency to H2 relaxin. Anti-fibrotic mechanism involves RXFP1-angiotensin II type 2 receptor heterodimers, pERK1/2, and MMP-2. PMID 30155023 Hossain MA et al. Chemical science (2016)
- B7-33 (0.25 mg/kg/day s.c., days 7–14 post-injury) equivalently reduced LV fibrosis and normalized LV inflammation and cardiomyocyte hypertrophy compared to H2 relaxin (0.5 mg/kg/day) in isoprenaline-induced cardiomyopathy in male 129sv mice. B7-33 provided more rapid anti-fibrotic effects than perindopril. PMID 36753958 Alam F et al. Biomedicine & pharmacotherapy (2023)
- B7-33 (0.25 mg/kg/day) in UUO-injured mice prevented renal fibrosis, correlating with reduced collagen fiber thickness and collagen-to-tissue cross reticulation ratio, and increased renal MMP-2 and reduced TIMP-1 levels over 7 days. PMID 33908676 Bhuiyan S et al. FASEB journal (2021)
- SPION-B7-33 (25 ng/day oral gavage every 72 h for 4 weeks) demonstrated greater anti-fibrotic efficacy than perindopril (60 ng/day) in mice with established cardiomyopathy. PMID 41382190 Somanader-Livera DVN et al. Journal of biomedical science (2025)
- Cardioprotection and attenuation of adverse cardiac remodeling after myocardial infarction Animal studies only
- B7-33 significantly reduced infarct size (21.99% vs 45.32%; P=0.02) and preserved fractional shortening (29% vs 23% at 24 h; 29% vs 20% at 7 days) compared with vehicle in adult male CD1 mice subjected to ischemia-reperfusion. In vitro, B7-33 (50–100 nmol/L) improved cardiomyocyte survival and reduced endoplasmic retic PMID 32295457 Devarakonda T et al. Journal of the American Heart Association (2020)
- Vasoprotection / endothelium-dependent relaxation Animal studies only
- B7-33 (13.3 µg/kg i.v. tail vein, acute bolus) enhanced bradykinin-mediated endothelium-dependent relaxation in rat mesenteric artery via endothelium-derived hyperpolarization, replicating effects of serelaxin. Co-incubation of B7-33 or serelaxin (15, 30 nM) with placental trophoblast conditioned media prevented endoth PMID 28478069 Marshall SA et al. European journal of pharmacology (2017)
- Reduction of fibrotic encapsulation of implantable devices (foreign body response) Animal studies only
- PLGA coatings releasing B7-33 reduced fibrotic capsule thickness by 49.2% over 6 weeks following subcutaneous implantation of polypropylene samples in mice. In vitro, B7-33 released from PLGA retained activity against RXFP1. PMID 31713411 Welch NG et al. ACS applied materials & interfaces (2019)
- Analgesia (central RXFP1 activation in inflammatory pain model) Animal studies only
- Intracerebroventricular injection of B7-33 produced a strong but transient reduction in mechanical and thermal sensitivity at 30 min post-injection in mice with CFA-induced inflammatory pain. Mechanical analgesia was blocked by co-injection of RXFP1 antagonist B-R13/17K-H2. PMID 34159282 Abboud C et al. Pain reports (2021)
- Anti-fibrotic therapy in cholangiocarcinoma stromal desmoplasia (nanovesicle-conjugated B7-33) Animal studies only
- cRGD-modified nanovesicles carrying B7-33 (B7-33-SNPs) synergistically disrupted CAF-angiogenesis crosstalk, reducing microvessel density and fibrotic deposition, achieving 67.7 ± 17.6% tumor growth inhibition in subcutaneous CCA xenograft models. PMID 41430305 Zhang L et al. Journal of nanobiotechnology (2025)
- Structure-activity relationship studies / peptide engineering (minimal relaxin scaffold) In vitro only
- Efforts toward a minimal H2 relaxin scaffold based on B7-33 were described, including Aib substitution and hydrocarbon stapling to recreate peptide helicity. B7-33 showed poor affinity in HEK cells overexpressing RXFP1 but equivalent potency to H2 relaxin in fibroblasts natively expressing RXFP1. PMID 37628851 Handley TNG et al. International journal of molecular sciences (2023)
- Fatty-acid conjugation with appropriate spacer length increased the in vitro half-life of B7-33 from ~6 min to 60 min without altering activity, as shown by structure-activity relationship studies. PMID 37047588 Praveen P et al. International journal of molecular sciences (2023)
- Review summarizing SAR studies leading to B7-33 as a single-B-chain-only agonist of RXFP1, describing its physiological functions in cellular and animal models. PMID 30641102 Praveen P et al. Molecular and cellular endocrinology (2019)
- Oral administration via nanoparticle conjugation (SPION-B7-33) for anti-fibrotic therapy Animal studies only
- SPION-B7-33 (25 ng/day via oral gavage every 72 h for 4 weeks from days 14–42 post-injury) demonstrated greater anti-fibrotic efficacy than perindopril in mice with established cardiomyopathy when conjugated to glycine-functionalised biodegradable SPIONs. SPIONs were likely phagocytosed by dendritic cells for systemic PMID 41382190 Somanader-Livera DVN et al. Journal of biomedical science (2025)
Safety signals
- Short in vitro serum half-life (~6 minutes for unmodified B7-33), which may limit systemic exposure and therapeutic duration PMID 37047588
- Preclinical only: no human safety data reported for B7-33 peptide in any reviewed abstract; all toxicity/tolerability data are from animal models PMID 30155023
- Parent hormone H2 relaxin (serelaxin) strong cAMP activation associated with potential tumor-promoting actions; B7-33 preferentially activates pERK and did not promote prostate tumor growth in preclinical models, but long-term oncological safety is not established PMID 30155023
Protocol
No community dose for B7-33 on record yet.
All studies (14)
- PMID 24941262
Not applicable — vobramitamab duocarmazine (anti-B7-H3 ADC) doses referenced are for a different compound, not B7-33 peptide Not applicable (animal) - PMID 28478069 Animal studies only
Vasoprotection / endothelium-dependent relaxation - PMID 30155023 Animal studies only
Anti-fibrotic effects (organ fibrosis — heart, lung, kidney) - PMID 30641102 In vitro only
Structure-activity relationship studies / peptide engineering (minimal relaxin scaffold) - PMID 31713411 Animal studies only
Reduction of fibrotic encapsulation of implantable devices (foreign body response) - PMID 32295457 Animal studies only
Cardioprotection and attenuation of adverse cardiac remodeling after myocardial infarction - PMID 33908676 Animal studies only
Anti-fibrotic effects (organ fibrosis — heart, lung, kidney) - PMID 34159282 Animal studies only
Analgesia (central RXFP1 activation in inflammatory pain model) - PMID 36753958 Animal studies only
Anti-fibrotic effects (organ fibrosis — heart, lung, kidney) - PMID 37047588 In vitro only
Structure-activity relationship studies / peptide engineering (minimal relaxin scaffold) - PMID 37628851 In vitro only
Structure-activity relationship studies / peptide engineering (minimal relaxin scaffold) - PMID 41382190 Animal studies only
Anti-fibrotic effects (organ fibrosis — heart, lung, kidney) - PMID 41430305 Animal studies only
Anti-fibrotic therapy in cholangiocarcinoma stromal desmoplasia (nanovesicle-conjugated B7-33) - PMID 41941262
Frequently asked
What is B7-33 and how does it work?
B7-33 is a synthetic single-chain peptide derived from the B-chain of human relaxin-2 (H2 relaxin). It acts as a functionally selective agonist of the G protein-coupled receptor RXFP1 (Relaxin Family Peptide Receptor 1), preferentially activating the pERK1/2 signaling pathway rather than the cAMP pathway. This selectivity is thought to underlie its anti-fibrotic effects while potentially avoiding tumor-promoting actions associated with strong cAMP activation by native H2 relaxin. Its anti-fibrotic mechanism involves activation of RXFP1-angiotensin II type 2 receptor heterodimers and downstream MMP-2.
What conditions has B7-33 been studied for?
Based on published preclinical studies: B7-33 has been studied for (1) organ fibrosis (heart, lung, kidney) in rodent models; (2) cardioprotection after myocardial infarction; (3) vasoprotection and endothelium-dependent relaxation in arterial models; (4) reduction of fibrotic encapsulation of implantable medical devices; (5) analgesia via central RXFP1 activation in inflammatory pain mouse models; and (6) anti-fibrotic effects in cholangiocarcinoma stroma when delivered via nanovesicles. All evidence is from animal or in vitro studies — no human clinical trials of B7-33 peptide itself were identified in the reviewed literature.
Has B7-33 been tested in humans?
No human clinical trials of B7-33 peptide were identified in the reviewed literature. All published studies are preclinical (animal models or in vitro cell studies). The parent molecule, H2 relaxin (serelaxin), has been clinically evaluated for heart failure (referenced in PMID 30155023), but B7-33 itself has not been reported in human trials in any of the reviewed abstracts.
What dose of B7-33 should I take?
I'm not a medical professional and can't recommend a protocol for you specifically. What research has shown: all dosing data for B7-33 come from animal studies only. Published doses include 0.25 mg/kg/day subcutaneously in mice, 13.3 µg/kg as a single intravenous bolus in rats, and 50–100 nmol/L in cell culture. No human dosing data exist in the reviewed literature. Do not extrapolate animal doses to human use.
Is B7-33 the same as B7-H3 or other B7 immune checkpoint proteins?
No. B7-33 is a relaxin-derived peptide — a single-chain analogue of the B-chain of human relaxin-2 that acts on RXFP1 receptors and has anti-fibrotic and vasoprotective properties. B7-H3 (CD276), B7-H4, B7-H5, etc. are immune checkpoint proteins of the B7 family involved in cancer immune regulation — they are entirely different molecules from B7-33. The shared 'B7' in the name is coincidental and reflects different naming conventions.
What are the known risks or side effects of B7-33?
No human safety or tolerability data for B7-33 are available in the reviewed literature. Preclinical observations include: a very short in vitro serum half-life (~6 minutes for unmodified B7-33; PMID 37047588), which may limit exposure. The parent hormone H2 relaxin has been associated with potential tumor-promoting effects linked to strong cAMP activation; B7-33 preferentially activates pERK and did not promote prostate tumor growth in one preclinical study, but long-term oncological safety has not been established. No contraindications are reported in the reviewed literature.
Can I take B7-33 with other peptides or compounds (stacking)?
I can't recommend combining compounds — that's a prescribing decision. Here's what has been studied individually: B7-33 has been studied alone or compared to H2 relaxin and the ACE inhibitor perindopril in animal models of fibrosis and cardiomyopathy. It has also been delivered via nanoparticle systems. No human combination data exist in the reviewed literature.
Where can I buy B7-33?
I don't recommend vendors or sources. Please consult a licensed provider.
Is B7-33 FDA approved?
The reviewed literature does not state any FDA approval or regulatory status for B7-33. The parent hormone H2 relaxin (serelaxin) was investigated for acute heart failure and received FDA Breakthrough Therapy designation, but development was discontinued after the RELAX-AHF-2 Phase 3 trial failed its primary endpoints in 2017; serelaxin is not FDA-approved. Its status would not carry over to B7-33 in any case. Regulatory status for B7-33 itself requires manual verification with current regulatory sources.
How is B7-33 different from H2 relaxin (serelaxin)?
B7-33 is a single-chain synthetic peptide derived from the B-chain only of H2 relaxin, whereas H2 relaxin is a two-chain, three-disulfide-bond peptide that is difficult to synthesize and costly to produce. Key differences described in the reviewed literature: (1) B7-33 preferentially activates pERK1/2 over cAMP at RXFP1, making it a functionally selective agonist, while H2 relaxin activates both pathways; (2) B7-33 did not promote prostate tumor growth in preclinical models, unlike H2 relaxin's strong cAMP activation which may have tumor-promoting effects; (3) B7-33 showed poor affinity in HEK cells overexpressing RXFP1 but equivalent potency to H2 relaxin in fibroblasts natively expressing RXFP1; (4) B7-33 has a very short in vitro serum half-life (~6 min; PMID 37047588); (5) B7-33 is simpler and less costly to synthesize.